V.A.C. VeraFlo™ Therapy
Cleanse, Treat, Heal
Prompt, appropriate, and effective wound management is more important than ever in reducing the economic and health consequences of wound management.\(^1\)

The use of advanced technologies, such as V.A.C.\(^\circledR\) Therapy, may lead to earlier wound closure and be more cost-effective compared to lower-cost products that take longer or fail to heal the wound.\(^2\)
V.A.C. VeraFlo™ Therapy is designed to work for many more

V.A.C. VeraFlo™ Therapy combines the benefits of V.A.C.® Therapy with automated solution distribution and removal. It can help:

- **Cleanse**: with instillation of topical wound cleansers in a consistent, controlled manner.
- **Treat**: infectious materials with the instillation of appropriate topical antimicrobial and antiseptic solutions.
- **Heal**: the wound and prepare for primary or secondary closure.

Moving toward a better negative-pressure wound therapy (NPWT) outcome

<table>
<thead>
<tr>
<th></th>
<th>NPWT</th>
<th>V.A.C. VeraFlo™ Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevent further wound contamination</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Manage excess exudates</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Optimise wound bed</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cleanse the wound</td>
<td>Only at dressing changes</td>
<td>Automatic repetitive cleansing</td>
</tr>
<tr>
<td>Provide antimicrobial antiseptic therapy</td>
<td>Only at dressing changes</td>
<td>Automatic repetitive treatment</td>
</tr>
</tbody>
</table>

Does your NPWT product provide these benefits?
In a porcine study with V.A.C. VeraFlo™ Therapy, 43% more granulation tissue was present after 7 days versus standard NPWT\(^3,4\)

V.A.C. VeraFlo™ Therapy with saline solution instillation significantly increased wound fill after 7 days of therapy compared to NPWT alone.\(^3\)

Mean granulation tissue thickness after 7 days of therapy (n=12)

At day 7, granulation tissue thickness was 43% greater (\(P<.05\)) in porcine wounds receiving V.A.C. VeraFlo™ Therapy with V.A.C. VeraFlo™ Dressings and saline instillation compared to wounds treated with V.A.C.® Therapy with V.A.C.® GranuFoam™ Dressings.\(^3\)

Note: Findings in animal studies have not yet been correlated in humans.

Data from an *in vitro* biofilm model indicate that V.A.C. VeraFlo™ Therapy, combined with appropriate wound solutions, may help control the bacteria known to form biofilm compared to standard NPWT⁴

In this *in vitro* mature biofilm study, V.A.C. VeraFlo™ Therapy with polyhexamethylene biguanide (PHMB) (0.1%) was shown to reduce *Pseudomonas aeruginosa* bioburden by 99.8% (approximately 3-log reduction).⁴

![Graph showing Pseudomonas aeruginosa results (CFU/mL)](image)

V.A.C. VeraFlo™ Therapy provides instillation therapy that, in this study, was shown to reduce biofilm bioburden. A mature *Pseudomonas aeruginosa* biofilm model using pig skin was used. Instillation was 6 times in 24 hours with 10-minute hold time.

*Note:* Findings in animal studies have not yet been correlated in humans.

*Source:* KCI data on file.
A clinical study indicated that polyhexanide instillation may be effective as an adjunctive therapy to manage infected orthopedic implants (OIs)\(^5\)

<table>
<thead>
<tr>
<th>Retained</th>
<th>Not retained</th>
<th>Retained</th>
<th>Not retained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knees</td>
<td>3/3 (100%)</td>
<td>0/3 (0%)</td>
<td>5/7 (71.4%)</td>
</tr>
<tr>
<td>Hips</td>
<td>14/17 (82.4%)</td>
<td>3/17 (17.6%)</td>
<td>3/3 (100%)</td>
</tr>
<tr>
<td>Osteosynthesis material</td>
<td>2/2 (100%)</td>
<td>0/2 (0%)</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>19/22 (86.4%)</td>
<td>3/22 (13.6%)</td>
<td>8/10 (80%)</td>
</tr>
</tbody>
</table>

The results of this prospective, multicentre, single-arm, postmarket, observational study suggest that instillation therapy\(^\dagger\) with polyhexanide (PHMB) may be effective as an adjunctive therapy to manage infected orthopedic implants, independent of the type of infection (i.e. acute or chronic) or micro-organism. The results exceeded, or were similar to, what has been reported in the literature without the use of instillation therapy.\(^5\)

\(^\dagger\)Literature references are described in the publication. Table adapted from publication.


A 66-year-old male was admitted to hospital on February 10, 2012, with an infected hip (THA).

Initiation of V.A.C. VeraFlo™ Therapy on February 20, 2012. At each cycle, Lactated Ringer’s solution (40 mL) was instilled with a soak time of 15 minutes and V.A.C.® Therapy time of 3.5 hours at a pressure of -125mmHg.

Wound was thoroughly debrided and V.A.C. VeraFlo™ Dressing was applied.

V.A.C. VeraFlo™ Therapy was discontinued after just 3 days, achieving primary closure.

Clinical goal was met, no recurring infections to date.

As with any case, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient’s circumstances and condition.
A clinical study indicated that instillation therapy* with silver nitrate shortened the time to bioburden reduction, wound closure, and hospital discharge.\(^6\)

In this prospective clinical study of 15 patients with a variety of complex infected wounds, NPWT with silver nitrate instillation showed a significant decrease in the mean time to clear infection, wound closure, and hospital discharge compared with traditional wet-to-moist wound care.\(^6\)

In this prospective clinical study of 15 patients with a variety of complex infected wounds, NPWT with silver nitrate instillation showed a significant decrease in the mean time to clear infection, wound closure, and hospital discharge compared with traditional wet-to-moist wound care.\(^6\)

An instillation system used was V.A.C. Instill\textsuperscript{®} Therapy System, which is equivalent to V.A.C. VeraFlo\textsuperscript{™} Therapy.


A 56-year-old diabetic male with infected diabetic foot ulcer following amputation of 2\textsuperscript{nd} toe and cleaning plantar abscess.

Day 1
Initiation of V.A.C. VeraFlo\textsuperscript{™} Therapy on March 8, 2012. At each cycle, Lactated Ringer’s solution (22 mL) was instilled with a soak time of 15 minutes and V.A.C.\textsuperscript{®} Therapy time of 3.5 hours at a pressure of -125mmHg.

Day 5
Second dressing change performed on March 12, 2012, using V.A.C. VeraFlo\textsuperscript{™} Dressing. Wound is progressing very well.

Day 7
V.A.C. VeraFlo\textsuperscript{™} Therapy was discontinued after just 1 week. Treatment is continued using V.A.C.\textsuperscript{®} Therapy only, also using the V.A.C.Ulta\textsuperscript{™} Therapy System.

Clinical goals were met. No sign of infection and granulation tissue is progressing.
For more information about the V.A.C.Ulta™ Therapy System or a product demonstration, please ask your KCI Representative, or visit your local KCI website at www.www.kci-medical.sg.

<table>
<thead>
<tr>
<th>Part Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ULTDEV01</td>
<td>V.A.C.Ulta™ Therapy Unit</td>
</tr>
<tr>
<td>ULTF05SSM</td>
<td>V.A.C. VeraFlo™ Dressing, 5-pack, Small</td>
</tr>
<tr>
<td>ULTF05SM</td>
<td>V.A.C. VeraFlo™ Dressing, 5-pack, Medium</td>
</tr>
<tr>
<td>ULTCLOSM</td>
<td>V.A.C. VeraFlo Cleanse™ Dressing, 5-pack, Medium</td>
</tr>
<tr>
<td>ULTNK0500</td>
<td>V.A.C. VeraLink™ Cassette, 5-pack</td>
</tr>
<tr>
<td>ULTDU0500</td>
<td>V.A.C. VeraT.R.A.C. Duo™ Tube Set, 5-pack</td>
</tr>
</tbody>
</table>

*The V.A.C.Ulta™ Therapy Unit is compatible with all InfoV.A.C.® System Canisters. When using the V.A.C.Ulta™ System for V.A.C.® Therapy only, use V.A.C.® Dressings featuring SenstaT.R.A.C.™ Technology.

References
4. KCI data on file.
7. KCI internal data on file.

KCI Medical Asia Pte Ltd
50 Ubi Crescent, #01-01,
Singapore 408568
1800 742 9929
www.kci-medical.sg

NOTE: Specific indications, contraindications, warnings, precautions, and safety information exist for KCI products and therapies. Please consult a physician and product instructions for use prior to application. This material is intended for healthcare professionals.

©2012 KCI Licensing, Inc. All rights reserved. All trademarks designated herein are proprietary to KCI Licensing, Inc., its affiliates, and/or licensors. DGLA12-0092.5G (Rev. 2/13)